More tools:Markets·Screener·Research·Chat

SELLAS Life Sciences Group, Inc. Common Stock (SLS) Financial Statements

SELLAS Life Sciences Group, Inc. Common Stock
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001T223C9
XNAS · usd
13.96▲ 0.10 (0.72%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales—
EV / Revenue—
EV / EBITDA—
Financial Highlights
Revenue (TTM)—
Net Income (TTM)
EBITDA—
Diluted EPS (TTM)
EBITDA Margin—
Net Debt
Trading Information
Previous Close13.86
Day's Range13.32 – 14.37
52-Week Range1.39 – 15.88
Volume6.0M
Avg Volume6.6M
Share Statistics
Shares Outstanding
Employees13
ExchangeXNAS
Listed2008-03-12
Share count as of August 10, 2026
Loading Income Statement…
Key questions about SELLAS Life Sciences Group, Inc. Common Stock (SLS)
What is SELLAS Life Sciences Group, Inc. Common Stock's Market Cap?
SELLAS Life Sciences Group, Inc. Common Stock's Market Cap is $2.8B, based on as-reported figures from SEC (XBRL) filings.
What is SELLAS Life Sciences Group, Inc. Common Stock's Enterprise Value?
SELLAS Life Sciences Group, Inc. Common Stock's Enterprise Value is $2.7B, based on as-reported figures from SEC (XBRL) filings.
What is SELLAS Life Sciences Group, Inc. Common Stock's Net Income (TTM)?
SELLAS Life Sciences Group, Inc. Common Stock's Net Income (TTM) is -$32.5M, based on as-reported figures from SEC (XBRL) filings.
What is SELLAS Life Sciences Group, Inc. Common Stock's Diluted EPS (TTM)?
SELLAS Life Sciences Group, Inc. Common Stock's Diluted EPS (TTM) is -0.16, based on as-reported figures from SEC (XBRL) filings.
What is SELLAS Life Sciences Group, Inc. Common Stock's Net Debt?
SELLAS Life Sciences Group, Inc. Common Stock's Net Debt is -$138.3M, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Non-operating income:
Interest income
Total non-operating income
Net loss
Net loss per common share, basic (in dollars per share)
Net loss per common share, diluted (in dollars per share)